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Abstract
Epidemiological data suggests that the incidence of anal carcinoma is increasing and a signiﬁcant percentage of cases each
year result in death. There are numerous clinical features that should raise suspicion for anal cancer. Furthermore, benign
anal conditions warrant complete workup, including ﬂexible endoscopy and anoscopy, to rule out malignancy. In this video
presentation, various patient presentations are described that would raise suspicion of anal carcinoma. Also, various
clinical, endoscopic, and pathological features of carcinoma of the anal canal and perianal skin as well as benign anal
conditions and treatment options are shown. This article is part of an expert video encyclopedia.
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Video Related to this Article
Materials
• Colonoscope: Olympus endoscopes 180 series (Olympus
America, Center Valley, PA, USA).
• Anoscope: Galenica Inc., Quebec, Canada.
Background
Anal carcinoma is an infrequent neoplasm of the digestive
tract that is increasing in incidence. According to 2012
American Cancer Society statistics, anal cancer comprises 2.2%
of all digestive tract tumors; there were 6230 new cases and
780 deaths. This represents a clear increase from the 2007
data, wherein 4660 new cases of anal cancer were diagnosed
and 660 patients died secondary to the disease. In fact, an
increase in the incidence of anal carcinoma has been observed
worldwide over the last 30–40 years.1–6
Recognized risk factors for anal carcinoma include increased
number of sexual partners; coexistence of sexually transmitted
diseases, including human immunodeﬁciency virus (HIV) and
human papilloma virus (HPV) serotypes 16 and 18; history of
cervical, vulvar, or vaginal carcinoma; and use of immuno-
suppression after solid organ transplant. Other risk factors in-
clude previous irradiation, Crohn’s disease, anal intercourse,
cigarette smoking, and deletion of chromosomes 11q and
3p2.3,4 The most frequent tumor of the anal canal and perianal
skin is squamous cell carcinoma (SCC), comprising 80–85% of
all lesions.8 The most important etiologic factor in the devel-
opment of anal SCC is HPV. HPV causes anal intraepithelial
neoplasia (AIN) that progresses from low- to high-grade dys-
plasia and ultimately to invasive cancer. This pathological
progression mirrors that of cervical intraepithelial neoplasia.3
For many years, chronic irritation to the perineum and anal
canal was considered to be a precursor to the development of
anal cancer, but benign anal lesions are no longer thought to
contribute to the development of anal cancer.3 However, be-
nign anal lesions and cancer can coexist; therefore, physicians
must still maintain a high index of suspicion for malignant
disorders even in the presence of benign disorders such as
pruritus ani, anal ﬁssures, proctalgia fugax, proctitis, hemor-
rhoids, and anorectal ﬁstulae.7 Furthermore, Paget’s disease
presents as an erythematous and eczematous rash similar to
benign skin conditions but histologically represents intrae-
pithelial adenocarcinoma with characteristic Paget cells. Fifty
percent of patients with Paget’s disease harbor a colorectal
neoplasm. Bowen’s disease is synonymous with AIN 3 and
indicates carcinoma in situ when demonstrated histopatholo-
gically. Bowen’s disease presents as discrete, erythematous,
occasionally brown–red, pigmented, noninﬁltrating scaly or
crusted plaques, which sometimes have a moist surface or
even nodules. Anal carcinoma of the anal canal and perianal
skin can comprise of several histological subtypes, including
SCC, adenocarcinoma, mucinous adenocarcinoma, small cell
carcinoma, basal cell carcinoma, melanoma, and undifferen-
tiated carcinoma.3
Therefore, for any suspected anal malignancy, a detailed
physical examination, including visual inspection, digital
rectal examination, ﬂexible endoscopy, and anoscopy is indi-
cated. Colonoscopy is indicated in patients with increasing
age, weight loss, iron deﬁciency anemia, a family history
of inﬂammatory bowel disease or colorectal cancer, and/or
persistent anorectal bleeding.7 However, lesions of the
anal canal are difﬁcult to assess by ﬂexible endoscopy alone.
For any patient with an anal irregularity found on physical
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examination or with ‘trivial’ hematochezia, the next appro-
priate step in management is surgical consultation for ano-
scopy with biopsy under sedation/anesthesia. Anoscopy is
complementary to ﬂexible endoscopy and both modalities
should be employed in the appropriate clinical setting.
Clinical examination is required to evaluate tumor size,
and computed tomography (CT) or magnetic resonance im-
aging of the abdomen and pelvis are performed to complete
clinical staging. Positron emission tomography (PET)–CT may
improve sensitivity for detecting lymph node metastasis and
should be performed when available.8
The current recommendation for initial treatment of SCC
of the anal canal remains chemoradiotherapy using mito-
mycin- and 5-ﬂuorouracil-based regimens. Surgery is indi-
cated for patients who cannot tolerate the acute toxicity of
radiotherapy, have clinically palpable node disease, and/or
require salvage of recurrent or residual primary tumor after
chemoradiotherapy. For adenocarcinoma and SCC of the
anal margin, wide local excision can be performed for small,
well-differentiated tumors; however, abdominoperineal re-
section and chemoradiation should be used for lesions
greater than 2 cm. For basal cell carcinoma and melanoma,
wide local excision is adequate for favorable lesions. Follow-
up serves to identify patients in need of salvage surgery,
palliative care, and prevention of second colorectal cancers.
Follow-up should begin 6–12 weeks after completion of
treatment.3
Key Learning Points/Tips and Tricks
• Anal carcinoma is an infrequent neoplasm of the digestive
tract that is increasing in incidence.
• Recognized risk factors include:
J Increased number of sexual partners.
J Coexistence of sexually transmitted diseases such as HIV
and HPV serotypes 16 and 18.
J History of cervical, vulvar, or vaginal carcinoma.





J Deletion of chromosomes 11q and 3p2.
• Anal carcinoma of the anal canal and perianal skin com-




J Small cell carcinoma.
J Basal cell carcinoma.
J Melanoma.
J Undifferentiated carcinoma.
• The most frequent tumor of the anal canal and perianal
skin is SCC, comprising 80–85% of all lesions.
• The most important etiologic factor in the development of
anal SCC is HPV infection.
• HPV causes AIN that progresses from low- to high-grade
dysplasia and, ultimately, to invasive cancer.
• Cancer can coexist with benign anal conditions.
• Paget’s disease presents as an erythematous and eczema-
tous rash similar to benign skin conditions and manifests
histologically as intraepithelial adenocarcinoma with
characteristic Paget cells.
• Bowen’s disease is synonymous with AIN 3 and indicates
carcinoma in situ when identiﬁed histopathologically.
Scripted Voiceover
Time (min:sec) Voiceover text
00:04 Anal carcinoma is an infrequent neoplasm of the
gastrointestinal (GI) tract that is increasing in
incidence.
00:13 Anal carcinomas include the following histological
types.
00:20 The most common type is squamous cell
carcinoma.
00:28 Human papilloma virus (HPV) is the most
important etiological factor.
00:34 HPV causes anal intraepithelial neoplasia which
progresses from low-grade to high-grade
dysplasia.
00:47 This patient has anal warts, or condyloma
acuminate, on an enlarged anal papilla.
01:04 Whereas in this patient, only an enlarged anal
papilla is seen.
01:14 To better deﬁne the mucosal surface, examination
can be performed under narrow band imaging.
01:28 Signiﬁcant amount of warty tissues can be seen in
this patient during retroﬂexed examination.
01:57 This patient has signiﬁcant anal warts.
02:04 Anoscopy is being performed to determine the
extent of internal involvement.
02:23 The anal warts involve the distal anal canal.
02:32 Surgical removal of the external warts is being
performed.
02:42 For any suspected anal malignancy, a detailed
physical examination, including visual inspection,
digital rectal exam, ﬂexible endoscopy, and
anoscopy is indicated.
03:02 Anoscopy is complementary to ﬂexible endoscopy
and both modalities should be employed in the
appropriate clinical setting.
03:14 For any patient with anal irregularities found
on physical exam, the next appropriate
step of management is surgical consultation
for anoscopy with biopsy under sedation/
anesthesia.
03:32 Colonoscopy is indicated in patients with increasing
age, weight loss, iron-deﬁciency anemia, a family
history of inﬂammatory bowel disease or
colorectal cancer.
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03:54 These are pathological images of HPV associated
low grade anal intra-epithelial neoplasm.
04:30 Bowen’s disease is synonymous with anal
intraepithelial neoplasm (AIN) 3.
04:47 Histologically, carcinoma in situ or high grade
dysplasia is present.
05:03 These are pathological images of well differentiated
squamous cell carcinoma.
05:16 Moderately differentiated squamous cell
carcinoma.
05:30 In patients with Paget’s disease, erythematous and
eczematous rash can be seen.
05:41 Histologically, intraepithelial adenocarcinoma, with
characteristic Paget cells, are observed.
05:46 Thank you for your attention.
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